PMC8569136_01
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_02
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_03
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_04
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_05
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_06
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_07
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_08
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_09
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_10
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_11
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_12
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_13
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_14
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_15
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).
PMC8569136_16
New MRI lesions associated with the MS episodes occurred after ChAdOx1 nCoV-19 (AZD12222), mRNA-1273, Moderna and BNT162b2, Pfizer/BioNTech vaccine. The lesions are shown on T2 weighted images or on post-contrast T1 weighted images and are indicated by yellow arrows. (A) Case 1: C3 lesion; (B) Case 2: new enhancing lesion in corpus callosum and multiple white matter unenhanced lesions in periventricular areas and in the mesial occipital lobe; (C) Case 3: new enhancing lesion in the thoracic cord; (D) Case 4: multiple hyperintense lesions in the supra and infratentorial white matter, four of which are with contrast enhancement; (E) Case 5: new brain lesion with contrast enhancement. (F) Case 6: enhancing bulbar lesion; (G) Case 7: C3 lesion with contrast enhancement; (H) Case 8: new brain enhancing lesion; (I) Case 9: a new contrast enhancing lesion in the mesencephalon. (L) Case 10: new enhancing brain lesion. (M) Case 11: enhancing brain lesion with conspicuous oedema; (N) Case 12: a new active lesion with ring enhancement in the left frontal white matter. (O) Case 13: three new brain enhancing lesions, one of which is indicated by the arrow; (P) Case 14: three new enhancing lesions in the left temporal lobe and one, indicated here, in the left centrum semiovale; (Q) Case 15: two ring-enhancing lesions localized in the white matter adjacent to the left frontal horn and in the left middle periventricular region. (R). Case 16: new enhancing lesions, one of which is tumefactive, localized in the white matter of the left centrum semiovale.
fneur-12-765954-g0001.jpg
PMC8569136_16_fneur-12-765954-g0001.jpg
F1
On June 24, he underwent a brain MRI that, compared with a previous routine scan of May 20, 2021, showed a new tumefactive contrast-enhancing lesion in the left fronto-parietal white matter (Figure 1R).